Compliance with the U.S. Bioterrorism Act of 2002 has a new ally in North America

Due to the rapidly expanding user base of the Catellae Food Traceability System, Lyngsoe Systems announces the launch of their web-based RFID enabled Food Track & Trace solution in the United States. The Catellae system provides food and beverage manufacturers, distributors and restaurant chains with the tools needed to support compliance of the Food and Drug Administration (FDA) Bioterrorism Act of 2002.

The Bioterrorism Act of 2002 (BTA) requires the establishment and maintenance of records by most companies manufacturing, processing, packaging, transporting, distributing, receiving, holding, or importing food in the United States effective by December 2005.

"These records will be crucial for the FDA to deal effectively with food-related emergencies, such as deliberate contamination of food by terrorists," said Dr. Lester M. Crawford, Acting FDA Commissioner. "The ability to trace back will enable us to get to the source of contamination. The records also enable FDA to trace forward to remove adulterated food that poses a significant health threat in the food supply."1

The Catellae system is a complete, turnkey solution incorporating highly automated data capture technology, while utilizing existing corporate business systems to provide the required levels of record keeping and reporting in an enterprise environment. The system further allows companies in the food and beverage industries real-time visibility of their supply chains while optimizing their cost structures.

Due to increasing government and consumer pressure, companies in the food and beverage industries are increasingly looking for solutions to insure higher levels of quality and accuracy for the safety of the consumer while maintaining the drive for operational profitability. The Catellae system is currently being implemented in the McDonalds pan-European supply chain. This solution roll-out for McDonalds will encompass more than 3500 restaurants.

1) US Food and Drug Administration Press Release, December 6, 2004. (

Comments (0)

Add a Comment

This thread has been closed from taking new comments.

Editorial: +44 (0)1892 536363
Publisher: +44 (0)208 440 0372
Subscribe FREE to the weekly E-newsletter